ChemoCentryx, Inc. Company Profile

05:59 EDT 25th September 2017 | BioPortfolio

ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for autoimmune diseases, inflammatory disorders and oncology.
By leveraging our pioneering expertise in the field of chemokine research, ChemoCentryx has generated a broad portfolio of medicines targeting the chemokine system, with six product candidates currently in pre-clinical and clinical stages of development. Our pipeline includes: Traficet-EN™ currently in Phase II clinical studies and initially being developed for inflammatory bowel disease. Traficet-EN targets a chemokine receptor called CCR9, which regulates the trafficking of inflammatory cells to the digestive tract. In a separate program, ChemoCentryx intends to take a new drug candidate for multiple sclerosis and cardiovascular disease, targeting the receptor CCR2, into clinical trials this year. Also, two promising compounds targeting novel chemokine receptors are in development for the treatment of cancers. Lastly, ChemoCentryx has two partnered programs. A CCR1 antagonist is being co-developed with Forest Laboratories for autoimmune disorders and CXCR3 receptor antagonists are being developed by ChemoCentryx's partner, Amgen-SF (formerly Tularik).


850 Maude Avenue
Mountain View
United States of America


Phone: 650-210-2900
Fax: 650-210-2910

News Articles [15 Associated News Articles listed on BioPortfolio]

Reviewing Fortress Biotech

Fortress Biotech and ChemoCentryx are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, i...

ChemoCentryx Completes Initial Public Offering

MOUNTAIN VIEW, Calif., Feb. 13, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the completion of its initial public offering of 4,500,000 shares of common stock.  In ...

ChemoCentryx 2017 Q1 - Results - Earnings Call Slides

ChemoCentryx 2017 Q2 - Results - Earnings Call Slides

ChemoCentryx's (CCXI) CEO Thomas Schall on Q1 2017 Results - Earnings Call Transcript

ChemoCentryx's (CCXI) CEO Thomas Schall on Q2 2017 Results - Earnings Call Transcript

ChemoCentryx Reports First Quarter 2017 Financial Results

  Life Sciences Jobs   ...

ChemoCentryx Reports Second Quarter 2017 Financial Results And Recent Highlights

  Life Sciences Jobs   ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

This is an open-label, single dose, randomized, five-period, crossover study in healthy volunteers to assess the relative bioavailability of four GSK developed oral formulations of GSK1605...

Companies [2 Associated Companies listed on BioPortfolio]


ChemoCentryx is a privately held biopharma company specializing in the biology of chemokines, protein hormones that regulate the migration, or trafficking, of white blood cells around the body. Whit...

ChemoCentryx, Inc.

ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for autoimmune diseases, inflammatory disorders and oncology. By leveraging our pioneering expertis...

More Information about "ChemoCentryx, Inc." on BioPortfolio

We have published hundreds of ChemoCentryx, Inc. news stories on BioPortfolio along with dozens of ChemoCentryx, Inc. Clinical Trials and PubMed Articles about ChemoCentryx, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ChemoCentryx, Inc. Companies in our database. You can also find out about relevant ChemoCentryx, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...

Corporate Database Quicklinks

Searches Linking to this Company Record